SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported) February
1, 2006
CHEMBIO
DIAGNOSTIC, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
0-30379
|
88-0425691
|
||
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
||
|
of
Incorporation)
|
Identification
Number)
|
|||
|
3661
Horseblock Road
|
||||
|
Medford,
NY 11763
|
||||
|
(Address
of principal executive offices)
|
||||
|
631-924-1135
|
||||
|
(Registrant’s
Telephone Number)
|
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
2.02. Results of Operations and Financial Condition.
To
the
extent applicable, the information disclosed under Item 7.01 is
incorporated herein by reference.
ITEM
7.01. Regulation FD Disclosures.
On
February 1, 2006 the Registrant issued the press release titled “Chembio
Completes First Large Order To Uganda Since National Protocol Designation”
included herein as Exhibit 99.1.
ITEM
9.01. Financial Statements and Exhibits
(c) Exhibits.
| 99.1 |
Press
Release titled “Chembio Completes First Large Order
To Uganda Since National Protocol Designation” issued February 1,
2006.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date:
February 2, 2006 Chembio
Diagnostics, Inc.
By:
/s/
Lawrence A. Siebert
Lawrence
A. Siebert
Chief
Executive Officer
Exhibit
99.1 Press Release
CHEMBIO
COMPLETES FIRST LARGE
ORDER TO UGANDA SINCE NATIONAL PROTOCOL DESIGNATION
Evaluation
Conducted for Zambian Health Ministry Recommends Chembio’s
Tests
MEDFORD,
N.Y. - Feb 1, 2006 - Chembio Diagnostics Inc. (OTCBB:CEMI) reported that
during
the last five weeks it has shipped approximately $540,000 of the Company’s rapid
HIV tests to the Ministry of Health of the Republic of Uganda. As previously
announced by the Ugandan Ministry of Health, Chembio’s HIV 1/2
STAT-PAKTM
test is
designated as the confirmatory test in all of the national rapid HIV testing
protocols. This is the first large order that the Company has received as
a
result of this designation. Chembio made a shipment in late December for
$405,000 of the items purchased. The remaining $135,000 was shipped this
week.
“The
demand for HIV rapid tests is expected to increase in Uganda and other countries
in the region as public health officials are encouraging the use of rapid
testing devices to identify and diagnose infected individuals”, commented
Lawrence Siebert, Chembio’s President. “Chembio is the exclusive confirmatory
test that is used on those who test positive during initial screening, a
number
which varies with the prevalence of the disease in the groups tested. Overall,
Uganda’s demand for rapid HIV tests is expected to exceed several million tests
for 2006.”
Chembio
also announced that the company’s HIV 1/2 STAT-PAK, HIV 1/2 STAT-PAK Dipstick
and SURE CHECK® HIV tests have been evaluated and recommended for use in Zambia.
The Virology Laboratory at the University Teaching Hospital in Lusaka conducted
the evaluation for Zambia’s Ministry of Health. The evaluation found the
performance of Chembio’s tests to be comparable and in some respects superior to
other commercial tests in standard use in Zambia. During the evaluation,
four
specimens gave discrepant results between the Chembio test and the reference
test. A third tiebreaker test was used and confirmed the Chembio test results
were correct.
ABOUT
CHEMBIO
Chembio
Diagnostics, Inc. (Chembio) possesses expertise in the development and
manufacturing of rapid test products for various infectious diseases, including
HIV, Tuberculosis
and
Chagas Disease. References to Chembio Diagnostics, Inc. may actually refer
to
Chembio Diagnostic Systems, Inc.; the 100%-owned subsidiary of Chembio
Diagnostics, Inc. Chembio is located at 3661 Horseblock Road, Medford, NY
11763.
For additional information please visit www.chembio.com.
FORWARD-LOOKING
STATEMENTS
Statements
contained herein that are not historical facts may be forward-looking statements
within the meaning of the Securities Act of 1933, as amended. Forward-looking
statements include statements regarding the intent, belief or current
expectations of the Company and its management Such statements are estimates
only, as the Company has not completed the preparation of its financial
statements for those periods, nor has its auditor completed the audit of
those
results. Actual revenue may differ materially from those anticipated in this
press release. Such statements reflect management's current views, are based
on
certain assumptions and involve risks and uncertainties. Actual results,
events,
or performance may differ materially from the above forward-looking statements
due to a number of important factors, and will be dependent upon a variety
of
factors, including, but not limited to Chembio's ability to obtain additional
financing, to obtain regulatory approvals in a timely manner, and the demand
for
Chembio's products. Chembio undertakes no obligation to publicly update these
forward-looking statements to reflect events or circumstances that occur
after
the date hereof or to reflect any change in Chembio's expectations with regard
to these forward-looking statements or the occurrence of unanticipated events.
Factors that may impact Chembio's success are more fully disclosed in Chembio's
most recent public filings with the U.S. Securities and Exchange
Commission.
Contact:
Vince
Daniels/James Carbonara
The
Investor Relations Group 212-825-3210